arrow
S

Sasiwimol Ubolyam

hiv-nat thai red cross aids and infectious diseases research centre
H指数:30
被引数:3,182

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of Body Weight and Combined UGT1A1 and NR1I2 Polymorphisms on Dolutegravir Pharmacokinetics Among Thai People Living with HIV: A Population Pharmacokinetic Analysis

体重及UGT1A1和NR1I2基因多态性对泰国HIV感染者中多替拉韦药代动力学的影响:一项群体药代动力学分析

2026-10-010
OA
Leave no one behind: equity, innovation and integration in HIV care in Asia: highlights from the 28th Bangkok International Symposium on HIV medicine

不让任何人掉队:亚洲艾滋病护理中的公平、创新与整合——第28届曼谷国际艾滋病医学研讨会亮点

2026-04-030
PRE
Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients

利福喷丁每月一次用于潜伏性结核病治疗的药代动力学和耐受性研究:在血液透析患者中的研究

2025-12-010
PRE
The Association Between Genetic Polymorphisms of UGT1A1, ABCG2, and NR1I2 and Dolutegravir Pharmacokinetic Parameters in Thai People Living with HIV

UGT1A1、ABCG2和NR1I2基因多态性与泰国人类免疫缺陷病毒感染者达芦那韦药代动力学参数之间的关联

2025-11-200
OAAI
NAT2 Polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living With HIV: Insights From a Pharmacogenetic-Pharmacokinetic Cohort Study

NAT2多态性与抗结核药物诱导的肝毒性:基于泰国人类免疫缺陷病毒感染者药效遗传-药代动力学队列研究的见解

2025-10-010
PRE
A Prospective Evaluation of the Diagnostic Accuracy of the Point-of-Care VISITECT CD4 Advanced Disease Test in 7 Countries

对7个国家的定点照护VISITECT CD4晚期疾病测试的诊断准确性进行前瞻性评估

2024-07-242
OAAI
Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study
2024-01-292
OAAI
Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features
MBIO
IF4.7
2021-04-2714
OAAI